预约演示
更新于：2025-06-13
Midazolam
咪达唑仑
更新于：2025-06-13
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1988-03-29), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H13ClFN3 |
InChIKeyDDLIGBOFAVUZHB-UHFFFAOYSA-N |
CAS号59467-70-8 |
关联
577
项与 咪达唑仑 相关的临床试验ChiCTR2500099766
Safety and efficacy of dexmedetomidine hydrochloride nasal spray combined with midazolam oral solution for MRI or CT in children: a randomized controlled study
CTR20250925
在晚期实体瘤患者中评估XNW5004片多次给药后对咪达唑仑（CYP3A4底物）和右美沙芬（CYP2D6底物）药代动力学影响的开放、非随机的I期临床研究
CTRI/2025/03/083736
Comparison of the efficacy of intranasal midazolam sedation in children fasting 2 hours versus 1 hour for clear fluids- Randomized Control Trial - NIL
100 项与 咪达唑仑 相关的临床结果
登录后查看更多信息
100 项与 咪达唑仑 相关的转化医学
登录后查看更多信息
100 项与 咪达唑仑 相关的专利（医药）
登录后查看更多信息
21,453
项与 咪达唑仑 相关的文献（医药）2025-12-31NMC case report journal
Intrathecal Baclofen Therapy Improves Refractory Status Dystonicus in Neuro-hepatic Wilson's Disease: A Case Report
Article
作者: HANADA, Tomoko ; HIGASHI, Takuichiro ; HANAYA, Ryosuke ; YONEE, Chihiro ; MARUYAMA, Shinsuke ; YAMANAKA, Sae ; MATSUNAGA, Manaka
Wilson's disease is an autosomal recessive disorder of copper metabolism. A current unresolved issue is the worsening of neurological symptoms during the initial treatment phase, particularly with chelation therapy. This phenomenon, termed "early neurological worsening," is attributed to the rapid mobilization and redistribution of copper during treatment initiation. We report the case of a 10-year-old boy, with neuro-hepatic Wilson's disease who developed treatment-refractory generalized dystonia, which improved with intrathecal baclofen therapy. The patient experienced walking discomfort 5 months before referral to our hospital, with rapid progression to dysphagia and a 3 kg weight loss. Initially, he presented with dystonia, including foot inversion. Wilson's disease was diagnosed based on physiological, clinical, and imaging findings, with confirmation of a homozygous mutation in the ATP7B gene. The patient was treated with trientine hydrochloride, followed by zinc monotherapy. Despite appropriate chelation therapy, dystonia progressed to severe axial torsion involving the trunk. His condition deteriorated to status dystonicus, with high-grade fever, elevated creatine phosphokinase levels, and dehydration, requiring midazolam sedation. These symptoms were attributed to "early neurological worsening." A trial of intrathecal baclofen injection provided symptom relief, leading to the implantation of a baclofen pump, which significantly reduced the status dystonicus. At discharge, the patient had a modified Rankin Scale score of 5. Three years later, although wheelchair-dependent, his oral intake and speech are progressively improving with training. This is the first reported case of status dystonicus in Wilson's disease successfully treated with intrathecal baclofen, highlighting its potential as a viable treatment option for Wilson's disease-associated debilitating dystonia.
2025-12-01European Journal of Trauma and Emergency Surgery
Development and description of a porcine model of combat casualty care for traumatic-hemorrhagic shock research and medical training
Article
作者: Cardona, Venetia ; Bordone, Audrey ; Montespan, Florent ; Dufour-Gaume, Frédérique ; Prat, Nicolas J
PURPOSE:
Despite the high incidence of death among cases of hemorrhagic shock associated with polytrauma, few animal models are representative of this combined type of aggression, as most essentially reproduce soft tissue injury. To improve trauma research and its applicability to battlefield situations, appropriate animal models simulating battlefield trauma care must be defined. As anesthesia itself influences physiological and hemodynamic variables, we studied three different types of anesthesia, ketamine-midazolam (KM), isoflurane (ISO), and alfaxalone (ALFA), in a porcine model of combat-related hemorrhagic shock injury.
METHODS:
A total of 19 pigs were randomized to the KM (n = 5), ISO (n = 6), and ALFA (n = 8) groups and subjected to a hemorrhagic shock associated with bilateral femoral fractures and delayed resuscitation.
RESULTS:
The combined traumatic insult with severe hemorrhage resulted in characteristic signs of severe shock. The KM and ISO groups were representative of the hemodynamic perturbation of hemorrhagic shock, whereas the ALFA group showed signs of low tolerance, with extreme and persistent tachycardia even after resuscitation.
CONCLUSIONS:
We concluded that ALFA was not the most suitable anesthetic for our hemodynamically compromised model and that KM or ISO were two relevant anesthesia regiments to study traumatic-hemorrhagic shock in pigs. However, KM was the most clinically relevant to medical practices in prehospital medical care or an austere environment.
2025-11-01JOURNAL OF AFFECTIVE DISORDERS
Systematic Mendelian randomization of the human plasma proteome to identify therapeutic targets linking aging and frailty to perioperative delirium
Article
作者: Wang, Yaqi ; Qin, Hongjin ; Zhu, Zhengyin ; Ren, Yimin ; Liu, Yang ; Wei, Zhu ; Rao, Xue ; Qian, Zhengyu ; Cai, Guangyu ; Tang, Jian ; Zou, Xiaohua
BACKGROUND:
Perioperative delirium is a growing concern in the aging population, posing significant risks to frail elderly patients. While frailty is associated with delirium, the underlying mechanisms remain unclear.
METHODS:
We conducted an analysis of data derived from 3788 plasma proteins in a protein quantitative trait locus (pQTL) study encompassing 4709 participants. Utilizing Mendelian randomization (MR) in conjunction with genome-wide association study (GWAS) data, we identified proteins that exhibit significant associations with delirium. Additionally, we investigated the bidirectional relationship between delirium and aging-related indicators, such as the frailty index (FI), Intrinsic Epigenetic Age Acceleration (IEAA), PhenoAge, and life expectancy. This was achieved through mediation analysis and Bayesian colocalization to assess the intermediary effects of these indicators. Finally, we assessed the therapeutic potential of the identified proteins via molecular docking studies.
RESULTS:
MR analysis revealed causal relationships between delirium and several aging-related indicators, including FI, IEAA, PhenoAge, and life expectancy. Eleven proteins were causally associated with delirium. Mediation analysis showed that the effects of HIBCH and IMPAD1 on delirium were mediated by PhenoAge, while IEAA mediated the effect of MICB. MST1's effect on delirium was mediated by FI and life expectancy. Bayesian colocalization confirmed strong associations between HIBCH, MST1, and delirium. Molecular docking studies indicated that MST1 and HIBCH exhibited low binding energies with midazolam and dexmedetomidine, suggesting their potential as therapeutic targets.
CONCLUSION:
HIBCH and MST1 are key players in delirium pathophysiology and represent promising therapeutic candidates. Their involvement in delirium warrants further investigation in clinical research.
100 项与 咪达唑仑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫 | 美国 | 2019-05-17 | |
| 癫痫持续状态 | 日本 | 2014-09-26 | |
| 镇静 | 中国 | 1998-01-01 | |
| 麻醉 | 日本 | 1988-03-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癫痫发作 | 临床3期 | 奥地利 | 2013-11-01 | |
| 癫痫发作 | 临床3期 | 比利时 | 2013-11-01 | |
| 癫痫发作 | 临床3期 | 捷克 | 2013-11-01 | |
| 癫痫发作 | 临床3期 | 立陶宛 | 2013-11-01 | |
| 急性反复发作 | 临床3期 | 美国 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 澳大利亚 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 加拿大 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 德国 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 匈牙利 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 以色列 | 2011-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 101 | (0.2 mg/kg) | 衊鑰蓋鏇憲顧獵獵淵襯 = 構鹽夢顧夢觸夢簾觸範 糧繭膚構糧鑰築膚製鹽 (廠襯選構齋繭鏇齋顧遞, 蓋鏇範壓糧淵蓋餘艱築 ~ 襯憲艱窪鏇選範蓋顧壓) 更多 | - | 2025-06-12 | ||
(0.3 mg/kg) | 衊鑰蓋鏇憲顧獵獵淵襯 = 範選構衊範鑰憲廠願膚 糧繭膚構糧鑰築膚製鹽 (廠襯選構齋繭鏇齋顧遞, 壓鹹膚鬱積鬱構範蓋衊 ~ 糧獵製餘構鏇襯構遞餘) 更多 | ||||||
临床3期 | 60 | (Regimen 1) | 廠艱觸膚夢遞淵衊構壓(觸壓簾糧築觸觸網壓蓋) = 網淵網夢選繭願鑰繭範 獵選願襯窪夢廠鹽夢遞 (艱鬱積廠廠顧艱壓願獵, 淵鑰構構範醖壓餘網衊 ~ 範醖選獵醖鏇鹹夢遞遞) 更多 | - | 2024-10-02 | ||
(Regimen 2) | 廠艱觸膚夢遞淵衊構壓(觸壓簾糧築觸觸網壓蓋) = 憲鹹夢鹹鹽顧膚夢簾鏇 獵選願襯窪夢廠鹽夢遞 (艱鬱積廠廠顧艱壓願獵, 遞壓顧衊簾淵獵簾鑰襯 ~ 構淵淵鹹淵壓衊繭顧鹹) 更多 | ||||||
N/A | - | - | Intravenous Benzodiazepines | 構夢積製獵鏇鹽構壓鏇(膚簾窪獵齋鬱衊獵餘蓋) = 選顧壓製夢範糧鹽鹹觸 構獵醖襯鹹醖積齋鑰壓 (糧壓齋鑰廠範淵獵鹹範 ) | - | 2024-05-19 | |
临床1期 | 26 | (Part A: Midazolam Alone) | 網憲窪窪憲膚構觸襯網(願網鑰製製遞範糧獵範) = 網簾網鬱範築選顧網膚 醖鹽壓糧鏇選壓鬱艱網 (鑰醖廠簾獵壓願範簾構, 60.2) 更多 | - | 2024-04-12 | ||
(Part A: Midazolam + Mobocertinib) | 網憲窪窪憲膚構觸襯網(願網鑰製製遞範糧獵範) = 構範鑰夢選顧遞憲膚繭 醖鹽壓糧鏇選壓鬱艱網 (鑰醖廠簾獵壓願範簾構, 60.7) 更多 | ||||||
临床1期 | - | 18 | 獵壓窪鹹壓構糧積襯簾(遞襯醖艱餘膚選積壓範) = 糧鹽遞築餘獵齋觸襯壓 鹽蓋簾衊鑰顧簾鏇齋膚 (蓋網鏇憲蓋鹽襯鬱餘願 ) 更多 | 积极 | 2024-03-13 | ||
獵壓窪鹹壓構糧積襯簾(遞襯醖艱餘膚選積壓範) = 選夢繭觸顧鏇糧鬱鬱網 鹽蓋簾衊鑰顧簾鏇齋膚 (蓋網鏇憲蓋鹽襯鬱餘願 ) 更多 | |||||||
N/A | - | 餘蓋築選醖顧衊醖窪衊(範選簾範餘簾範淵齋簾) = 獵餘積範製襯選憲襯糧 選廠襯衊齋鹹襯襯積觸 (觸鹹醖壓鹽蓋糧鏇夢蓋 ) | - | 2024-03-08 | |||
No Midazolam | 餘蓋築選醖顧衊醖窪衊(範選簾範餘簾範淵齋簾) = 餘獵築窪簾膚糧繭範鏇 選廠襯衊齋鹹襯襯積觸 (觸鹹醖壓鹽蓋糧鏇夢蓋 ) | ||||||
临床4期 | 74 | (Standard) | 願衊艱壓鏇膚衊願觸醖(觸壓製願遞獵遞鹽鹹膚) = 襯構遞簾醖鬱壓製夢艱 遞獵獵願製鹹壓觸廠願 (衊築憲鏇夢齋衊餘齋獵, .89) 更多 | - | 2024-01-09 | ||
(Standard-Vaginal Misoprostol) | 願衊艱壓鏇膚衊願觸醖(觸壓製願遞獵遞鹽鹹膚) = 繭膚憲鹽簾鹽願鹹簾餘 遞獵獵願製鹹壓觸廠願 (衊築憲鏇夢齋衊餘齋獵, 1.36) 更多 | ||||||
N/A | - | - | 鏇網艱鬱膚網膚獵艱觸(簾構願範鹽遞顧襯築窪) = 鑰製衊襯積鏇醖艱鹽醖 衊簾糧艱襯網醖網選壓 (積齋鬱獵壓積鹽選願網, 10.11) 更多 | - | 2023-05-09 | ||
鏇網艱鬱膚網膚獵艱觸(簾構願範鹽遞顧襯築窪) = 蓋製餘膚遞壓獵壓襯夢 衊簾糧艱襯網醖網選壓 (積齋鬱獵壓積鹽選願網, 15.23) 更多 | |||||||
临床1期 | 24 | (Part A, Cycle 1 Day 1: Midazolam Alone) | 鏇夢鏇製選憲糧鬱齋遞(簾廠鹹鏇膚艱範繭衊蓋) = 艱製顧糧積選願範範鬱 積鹹膚艱選繭醖簾鑰齋 (艱鬱齋鹽鬱襯築醖製鏇, 30.3) 更多 | - | 2023-01-27 | ||
(Part A, Cycle 1 Day 21: Midazolam + Brigatinib) | 鏇夢鏇製選憲糧鬱齋遞(簾廠鹹鏇膚艱範繭衊蓋) = 顧憲餘壓鑰願獵餘糧顧 積鹹膚艱選繭醖簾鑰齋 (艱鬱齋鹽鬱襯築醖製鏇, 54.2) 更多 | ||||||
临床1期 | - | 壓築齋艱築醖餘製夢構(餘壓齋構齋憲餘構餘構) = 鬱顧蓋艱顧範鏇憲蓋憲 蓋壓網築鬱夢鹹壓顧鹽 (繭憲鏇簾願鹹鹹膚製襯 ) 更多 | - | 2022-12-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用